The upconversion luminescence biomonitoring and biological properties of rare earth oxide-inorganic composite microspheres enhanced by lithium

Multiple myeloma is the second most common hematologic malignant tumor, which can result in complications such as osteolytic fractures and bacterial infections. The side effects of chemotherapy limit the dosage of drugs, which can easily lead to multidrug resistance. Moreover, the dose and distribution of drugs within the body significantly influence the therapeutic efficacy of drugs. Therefore, it is highly necessary to improve multidrug resistance and bacterial infection in the treatment of multiple myeloma, repair bone defects caused by bone pain, and monitor the real-time dynamics of drugs. This work proposes a novel rare earth oxide-inorganic composite (7Li-MBGs:2Er/2Yb-0.75MTO) as a drug delivery platform for the treatment of multiple myeloma. 7Li-MBG, which have bone repair functions, serve as inorganic matrix materials, while Er 2 O 3 and Yb 2 O 3 act as activators and sensitizers, respectively. MTO is used as a therapeutic drug for treating myeloma. The drug release process of MTO was successfully monitored by upconversion luminescence. Cell experiments confirmed that 7Li-MBGs:2Er/2Yb-0.75MTO has a certain long-term therapeutic effect on multiple myeloma, and its mechanism of action is consistent with its drug release kinetics. Moreover, the synergistic effect of rare earth oxides, alkali metal ions and MTO endows 7Li-MBGs:2Er/2Yb-0.75MTO with high antibacterial and osteoinductive abilities, and thus playing a role in enhancing the drug resistance of infectious bacteria, preventing bacterial infection, repairing bone defects and monitoring the real-time dynamics of drug release during multiple myeloma therapy. Therefore, the 7Li-MBGs:2Er/2Yb-0.75MTO multifunctional drug delivery platform synthesized in this work provides a new idea for the treatment of multiple myeloma and biomonitoring.